| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| New Podcast and Special Report Explore How AI Is Revolutionizing Drug Discovery and Development | Editors | 09/02/20 | National |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Kinnate Raises $98M for Human Tests of Targeted Cancer Therapies | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| FDA Rejects Tricida Chronic Kidney Disease Drug, More Data Needed | Frank Vinluan | 08/25/20 | San Francisco |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Astellas Reports Third Patient Death in Audentes Gene Therapy Study | Frank Vinluan | 08/21/20 | San Francisco |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| FDA Rejects BioMarin Hemophilia Gene Therapy, Asks for More Data | Sarah de Crescenzo | 08/19/20 | National |
| Unity Biotech Arthritis Drug Flunks Phase 2, Spelling Program’s End | Frank Vinluan | 08/18/20 | San Francisco |
| Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug | Sarah de Crescenzo | 08/18/20 | San Francisco |
| Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor | Sarah de Crescenzo | 08/17/20 | Boston |
| Sanofi Reaches $3.68B Deal to Buy Principia and Partnered MS Drug | Frank Vinluan | 08/17/20 | Europe |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| Perceptive Advisors’ LianBio Inks Deals With BridgeBio, MyoKardia | Sarah de Crescenzo | 08/12/20 | San Francisco |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
| Biogen to Pay Denali $1B to Partner on Parkinson’s Drug & Other Neuro Meds | Frank Vinluan | 08/06/20 | San Francisco |
| IgGenix Grabs $10M to Advance Antibody Treatments for Allergies | Sarah de Crescenzo | 08/05/20 | San Francisco |
| As Patients Pivot to Telehealth, Teladoc & Livongo Plan $18.5B Tie-Up | Frank Vinluan | 08/05/20 | New York |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| CymaBay PBC Drug Hits Phase 3 Goals With Signs of Side Effect Advantage | Sarah de Crescenzo | 08/04/20 | San Francisco |
| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D | Sarah de Crescenzo | 07/30/20 | San Francisco |
